Endo International PLC (NASDAQ:ENDP) Short Interest Update

Endo International PLC (NASDAQ:ENDP) (TSE:ENL) was the target of a significant drop in short interest in the month of December. As of December 31st, there was short interest totalling 31,730,000 shares, a drop of 5.6% from the December 15th total of 33,620,000 shares. Based on an average trading volume of 7,940,000 shares, the days-to-cover ratio is presently 4.0 days. Currently, 15.6% of the shares of the company are sold short.

Several institutional investors and hedge funds have recently bought and sold shares of ENDP. Russell Investments Group Ltd. raised its holdings in Endo International by 56.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 167,064 shares of the company’s stock valued at $689,000 after buying an additional 60,234 shares during the last quarter. Commonwealth Bank of Australia raised its holdings in Endo International by 41.6% in the 2nd quarter. Commonwealth Bank of Australia now owns 66,400 shares of the company’s stock valued at $273,000 after buying an additional 19,500 shares during the last quarter. Paloma Partners Management Co bought a new position in Endo International during the 2nd quarter worth approximately $98,000. UBS Asset Management Americas Inc. raised its holdings in Endo International by 8.9% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 196,692 shares of the company’s stock worth $810,000 after purchasing an additional 16,125 shares during the last quarter. Finally, United Services Automobile Association increased its stake in shares of Endo International by 6.4% in the 2nd quarter. United Services Automobile Association now owns 218,890 shares of the company’s stock valued at $902,000 after acquiring an additional 13,126 shares in the last quarter. Institutional investors own 97.03% of the company’s stock.

Endo International stock traded down $0.22 during trading hours on Friday, reaching $5.96. 191,327 shares of the stock were exchanged, compared to its average volume of 7,513,652. The company has a market cap of $1.39 billion, a P/E ratio of 2.07 and a beta of 1.41. Endo International has a twelve month low of $1.97 and a twelve month high of $12.49. The stock has a 50 day moving average of $4.80 and a two-hundred day moving average of $3.94.

Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.53 by $0.07. The firm had revenue of $729.00 million for the quarter, compared to the consensus estimate of $709.01 million. Endo International had a negative net margin of 16.89% and a negative return on equity of 99.08%. The business’s revenue for the quarter was down 2.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.71 earnings per share. On average, sell-side analysts predict that Endo International will post 2.21 earnings per share for the current year.

A number of equities analysts recently commented on the stock. BidaskClub raised shares of Endo International from a “sell” rating to a “hold” rating in a research report on Tuesday, December 3rd. Piper Jaffray Companies raised shares of Endo International from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $5.00 to $7.00 in a research report on Friday, January 3rd. Finally, ValuEngine raised shares of Endo International from a “sell” rating to a “hold” rating in a research report on Friday, January 3rd. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and three have assigned a buy rating to the stock. Endo International presently has an average rating of “Hold” and an average price target of $7.70.

Endo International Company Profile

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Featured Story: What are the benefits of a balanced fund?

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.